Patent ID: 11938192
Assignee: MEDIMMUNE LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating a subject suffering from a proliferative disease, said method comprising:
administering to a subject suffering from a proliferative disease an effective amount of a CD19-antibody drug conjugate (ADC),
wherein (i) the CD19-ADC comprises as the a pyrrolobenzodiazepine (PBD) dimer, linked to an antibody that binds to CD19; and (ii) the CD19-ADC has a drug to antibody ratio (DAR) of between 1 and 8,
wherein (i) the CD19-ADC is administered to the subject in a dosage regime comprising at least two treatment cycles; and (ii) the dose of CD19-ADC is reduced following the second treatment cycle; and
wherein (i) the proliferative disease is a CD19+ cancer or a CD19+ autoimmune disease; and (ii) the PBD dimer is of formula I:, , wherein, (a) RL1′ is a linker for connection to Ab, wherein RL1′ is, , wherein the wavy line indicates the point of attachment to the Ab and the asterisk indicates the point of attachment to the nitrogen in Formula (I);, (b) (i) R20 and R21 either together form a double bond between the nitrogen and carbon atoms to which they are bound; or (ii) R20 is a capping group RC, and R21 is OH;, (c) m is 0 or 1; and, (d) when there is a double bond between C2 and C3, R2 is methyl;, , when there is a single bond between C2 and C3, R2 is either H or, when there is a double bond between C2′ and C3′, R12 is methyl;, when there is a single bond between C2′ and C3′, R12 is H or,